Stock Research for SPHS


Featured Broker: Ally Invest

Get the due diligence for another stock.


SPHS Stock Chart & Research Data

The SPHS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SPHS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


SPHS Due diligence Resources & Stock Charts

The SPHS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SPHS Detailed Price Forecast - CNN Money CNN View SPHS Detailed Summary - Google Finance
Yahoo View SPHS Detailed Summary - Yahoo! Finance Zacks View SPHS Stock Research & Analysis -

Stock Analysis

TradeIdeas View SPHS Trends & Analysis - Trade-Ideas Barrons View SPHS Major Holders - Barrons
NASDAQ View SPHS Call Transcripts - NASDAQ Seeking View SPHS Breaking News & Analysis - Seeking Alpha
Spotlight View SPHS Annual Report - OTC Report View SPHS OTC Short Report -
TradeKing View SPHS Fundamentals - TradeKing Charts View SPHS SEC Filings - Bar Chart
WSJ View Historical Prices for SPHS - The WSJ Morningstar View Performance/Total Return for SPHS - Morningstar
MarketWatch View the Analyst Estimates for SPHS - MarketWatch CNBC View the Earnings History for SPHS - CNBC
StockMarketWatch View the SPHS Earnings - StockMarketWatch MacroAxis View SPHS Buy or Sell Recommendations - MacroAxis
Bullish View the SPHS Bullish Patterns - American Bulls Short Pains View SPHS Short Pain Metrics -

Social Media Mentions

StockTwits View SPHS Stock Mentions - StockTwits PennyStocks View SPHS Stock Mentions - PennyStockTweets
Twitter View SPHS Stock Mentions - Twitter Invest Hub View SPHS Investment Forum News - Investor Hub
Yahoo View SPHS Stock Mentions - Yahoo! Message Board Seeking Alpha View SPHS Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for SPHS - Insider Cow View Insider Transactions for SPHS - Insider Cow
CNBC View SPHS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SPHS - OTC Markets
Yahoo View Insider Transactions for SPHS - Yahoo! Finance NASDAQ View Institutional Holdings for SPHS - NASDAQ

Stock Charts

FinViz View SPHS Stock Insight & Charts - StockCharts View SPHS Investment Charts -
BarChart View SPHS Stock Overview & Charts - BarChart Trading View View SPHS User Generated Charts - Trading View

Latest Financial News for SPHS

Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement
Posted on Friday September 14, 2018

SAN DIEGO and VANCOUVER, British Columbia, Sept. 14, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that it has met the requirements within its existing loan and security agreement with Silicon Valley Bank ("SVB") to extend the interest only periods between September 30, 2018 and March 31, 2019. The Company will begin making interest and principal payments starting on April 1, 2019 and ending on the final payment date of September 1, 2021. The extension of this interest only period allows the Company to shift principal payments of $1.2 million, which would have been due during the periods between September 30, 2018 and March 31, 2019, to periods after April 1, 2019.

SPHS: Patient Death in Phase 2b Trial Unlikely Related to Topsalysin Treatment…
Posted on Thursday August 30, 2018

On August 29, 2018, Sophiris Bio, Inc. (SPHS) announced the result of an investigation into the previously announced patient death in the ongoing Phase 2b trial of topsalysin (PRX302) in localized clinically significant prostate cancer. After reviewing the autopsy report, hospital records, and hypersensitivity tests, it was determined that the patient’s death was unlikely the result of topsalysin or the procedure. The official cause of death listed on the autopsy report is Sudden Cardiac Deach (SCD) probably due to arrhythmia and the patient had a number of risk factors for SCD.

Today’s Research Reports on Stocks to Watch: Opiant Pharmaceuticals and Sophiris Bio
Posted on Thursday August 30, 2018

NEW YORK, NY / ACCESSWIRE / August 30, 2018 / Shares of Opiant saw big gains after Wall Street learned that Emergent Biosciences Inc. announced the acquisition of Adapt Pharma® for $635 million. Adapt markets NARCAN® Nasal Spray for the treatment of opioid overdose, for which Opiant Pharmaceuticals, Inc. receives tiered royalties. Shares of Sophiris Bio also saw big gains after announcing updates on a phase 2b Localized Prostate Cancer Trial.

Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Posted on Wednesday August 29, 2018

SAN DIEGO and VANCOUVER, British Columbia , Aug. 29, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

Stock Market & Investing Books

Enter a stock symbol to view the stock details.